NovaSterilis specializes in the sterilization and processing of biological materials using supercritical CO2 (scCO2) technology. The company serves a diverse range of clients, including those in the medical, pharmaceutical, and biotechnology sectors. Operating in the sterilization and biomaterial modification market, NovaSterilis employs a business model centered around contract research services and the sale of sterilization equipment. Revenue is generated through feasibility studies, material exposure testing, and the commercialization of their Nova2200 and Nova8800 sterilization systems. The company’s expertise lies in identifying key scCO2 operating parameters and ensuring regulatory compliance for various applications. NovaSterilis also focuses on developing unique material functionalities through structural modification development (SMD), which involves extensive testing of temperature, pressure, and other parameters. The company’s innovative approach has made it a leader in the field, providing cost-effective and efficient sterilization solutions.

Keywords: supercritical CO2, sterilization, biomaterials, medical devices, pharmaceuticals, biotechnology, contract research, feasibility studies, Nova2200, Nova8800.